CASI Pharmaceuticals (CASI)
US Market

CASI Pharmaceuticals (CASI) Stock Price & Analysis


CASI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.45 - $3.70
Previous Close$2
Average Volume (3M)10.75K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$49.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.0
Nov 14, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding13,320,000
10 Day Avg. Volume7,042
30 Day Avg. Volume10,754
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)0.63
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside365.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was CASI Pharmaceuticals’s price range in the past 12 months?
CASI Pharmaceuticals lowest stock price was $1.45 and its highest was $3.70 in the past 12 months.
    What is CASI Pharmaceuticals’s market cap?
    Currently, no data Available
    When is CASI Pharmaceuticals’s upcoming earnings report date?
    CASI Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is in 53 days.
      How were CASI Pharmaceuticals’s earnings last quarter?
      CASI Pharmaceuticals released its earnings results on Aug 11, 2023. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.27.
        Is CASI Pharmaceuticals overvalued?
        According to Wall Street analysts CASI Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does CASI Pharmaceuticals pay dividends?
          CASI Pharmaceuticals does not currently pay dividends.
          What is CASI Pharmaceuticals’s EPS estimate?
          CASI Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does CASI Pharmaceuticals have?
          CASI Pharmaceuticals has 13,321,507 shares outstanding.
            What happened to CASI Pharmaceuticals’s price movement after its last earnings report?
            CASI Pharmaceuticals reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went up 3.556%.
              Which hedge fund is a major shareholder of CASI Pharmaceuticals?
              Among the largest hedge funds holding CASI Pharmaceuticals’s share is Consonance Capital. It holds CASI Pharmaceuticals’s shares valued at N/A.


                CASI Pharmaceuticals Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                CASI Pharmaceuticals

                CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.


                Top 5 ETFs holding CASI

                Market Value
                Smart Score
                Vanguard Total Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold CASI. The ETFs are listed according to market value of CASI within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Cellectar Biosciences
                Aurinia Pharmaceuticals
                Bellicum Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis